HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody

Launched by SHANGHAI GENERAL HOSPITAL, SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · Dec 14, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new way to detect and treat breast cancer using a special type of imaging and therapy. Researchers want to see how safe and effective a treatment that uses two radioactive substances (99mTc and 188Re) attached to an antibody that targets HER2, a protein often found in some breast cancers, is for patients. This method aims to provide a non-invasive way to check for HER2 expression in breast cancer, which is important for guiding treatment decisions.

To participate, you need to be a female adult (18 years or older) who has been diagnosed with breast cancer and is willing to provide written consent. You should also have HER2-positive cancer that has progressed after standard treatments like surgery and chemotherapy. Participants will undergo imaging tests and receive treatment, while doctors closely monitor their safety and response. Notably, women who are pregnant or breastfeeding, or those with certain health conditions, are not eligible for this trial. If you're considering joining, it could be an opportunity to help advance breast cancer treatment while receiving specialized care.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult female, age 18 years or older
• • 2. Prior diagnosis of breast cancer
• • 3. Willing to participate in this study and given written informed consent
• • 4. AST, ALT, BUN, Cr not more than double the normal values
• • 5. Subjects of childbearing potential must be willing to undergo a pregnancy test prior to enrolment
• • Patients will only be included in the 188Re-NM-02 study if they meet the following supplementary criterial: HER2 postive, progression or recurrence after standard treatment, including surgery, chemotherapy, radiotherapy and targeted therapy.
• Exclusion Criteria:
• • 1. Pregnancy (subjects with a positive pregnancy test at baseline screening period or who are planning to become pregnant during the study period)
• • 2. Breastfeeding (subjects in lactation)
• • 3. No biopsy tissue sample can be provided for HER2 expression detection
• • 4. Subjects with pacemakers
• • 5. Hepatitis B virus infection (including carriers) at screening, ie hepatitis B surface antigen (HBsAg) positive, or hepatitis C antibody (anti-HCV) positive, or acquired immunodeficiency disease (HIV) infected, or serum syphilis positive person
• • 6. Abnormal liver function during baseline screening period : AST or ALT\> 2 times the upper limit of normal value (ULN), if the marginal increase of a single index is judged as having no clinical significance by the investigator, it can be retested during the screening period. Once, if ≤ 2 times ULN after retesting, consider enrolling).
• • 7. Impaired renal function during screening: serum creatinine or urea nitrogen \> 1.5 times ULN.
• • 8. Within 4 months prior to the baseline screening period , myocardial infarction or other cardiac events requiring hospitalization (unstable angina, etc.), cerebrovascular accident, transient ischemic attack, acute congestive Heart failure or severe arrhythmia (ventricular arrhythmia, atrioventricular block above II)
• • 9. Subjects with pulmonary embolism or deep vein thrombosis
• • 10. Various infections that the investigators consider unsuitable for study, including but not limited to patients with various infections requiring further treatment, such as urinary tract infections, respiratory infections, and diabetic foot infections.
• • 11. Patients with abnormal thyroid function during baseline screening period (including but not limited to active hyperthyroidism, hypothyroidism or Hashimoto's thyroiditis)